(NASDAQ: CNTB) Connect Biopharma Holdings's forecast annual revenue growth rate of 703.56% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.97%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.92%.
Connect Biopharma Holdings's revenue in 2026 is $233,000.On average, 9 Wall Street analysts forecast CNTB's revenue for 2026 to be $1,727,728,126, with the lowest CNTB revenue forecast at $83,741,924, and the highest CNTB revenue forecast at $6,828,429,858. On average, 9 Wall Street analysts forecast CNTB's revenue for 2027 to be $4,834,364,633, with the lowest CNTB revenue forecast at $0, and the highest CNTB revenue forecast at $18,962,823,608.
In 2028, CNTB is forecast to generate $7,513,476,578 in revenue, with the lowest revenue forecast at $920,972,278 and the highest revenue forecast at $18,148,700,989.